Coherus director granted RSUs, 60K stock options
Coherus Oncology director Ali J. Satvat received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology director Ali J. Satvat received new equity awards. On June 5, 2026, he was granted 30,000 restricted stock units, each convertible into one share of common stock upon vesting. According to the terms, all RSUs vest 100% on the one-year anniversary of June 3, 2026, subject to his continued service.
He also received a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share. This option vests and becomes fully exercisable on June 3, 2027, conditional on his continued service with the company, and expires on June 5, 2036.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
Satvat Ali J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 30,000 shares (Direct)
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSU grant: 30,000 units
RSU vesting date: One-year anniversary of June 3, 2026
Option grant size: 60,000 shares
+5 more
8 metrics
RSU grant
30,000 units
Restricted stock units granted June 5, 2026
RSU vesting date
One-year anniversary of June 3, 2026
100% of RSUs vest on this date, subject to service
Option grant size
60,000 shares
Stock option (right to buy) granted June 5, 2026
Option exercise price
$1.45 per share
Exercise price for 60,000-share stock option
Option vesting date
June 3, 2027
Option becomes fully exercisable on this date
Option expiration
June 5, 2036
Expiration date of the stock option grant
Shares following RSU grant
30,000 shares
Total common stock reported following RSU acquisition
Options following grant
60,000 options
Total derivative securities reported following option grant
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy, vesting, exercisable, +1 more
5 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with 60,000.0000 shares and a $1.4500 exercise price..."
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercisable financial
"The underlying shares vest and become exercisable as to 100% of the total number..."
exercise price financial
"conversion_or_exercise_price of 1.4500 per share for the stock option grant..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Coherus Oncology (CHRS) director Ali J. Satvat receive in this Form 4?
Ali J. Satvat received equity-based compensation consisting of 30,000 restricted stock units and a stock option for 60,000 shares. Both awards are subject to future vesting based on his continued service with Coherus Oncology.
How many Coherus Oncology (CHRS) RSUs were granted to Ali J. Satvat?
He was granted 30,000 restricted stock units, each representing the right to receive one share of common stock upon vesting. All RSUs are scheduled to vest 100% on the one-year anniversary of June 3, 2026, subject to continued service.
What are the terms of Ali J. Satvat’s stock option grant at Coherus Oncology (CHRS)?
He received a stock option covering 60,000 shares of common stock at a $1.45 exercise price. The option vests fully on June 3, 2027, contingent on continued service, and carries an expiration date of June 5, 2036.
When do Ali J. Satvat’s Coherus Oncology (CHRS) RSUs vest?
The restricted stock units vest 100% on the one-year anniversary of June 3, 2026. Vesting is conditioned on Satvat maintaining a continued service relationship with Coherus Oncology through that vesting date, as described in the award terms.
When do Ali J. Satvat’s Coherus Oncology (CHRS) stock options become exercisable?
The underlying shares subject to the option vest and become exercisable as to 100% of the 60,000 shares on June 3, 2027. This vesting and exercisability depend on Satvat’s continued service with the company until that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
